ADC/Labs to Collaborate with Klee
News Nov 01, 2005
The intention is to deliver an integrated product, delivering access to the industry standard nomenclature and physicochemical prediction algorithms via the Kalabie electronic notebook, with the intention of delivering more efficient and repeatable discovery processes.
Alain Meller, Kalabie Director at Klee Group comments, "ACD/Labs is certainly one of the key specialty software companies in the marketplace. With this agreement we will tighten our relationship and provide a seamless integration between Kalabie and ACD/labs products.
We believe that major challenges for ELNs and Collaborative R&D environments revolve around integration: integration with a customer's information services environment and integration with partner software like ACD/Labs. Kalabie in this respect can capitalize on 20 years of history of successes and experience of the Klee Group."
Antony Williams, VP and Chief Science Officer for ACD/Labs, furthers, “Electronic Notebooks are permeating the life sciences industry and delivering standardized platforms for electronic recordkeeping.
The Kalabie platform is recognized as one of the guiding lights in the developing ELN marketplace and the connection of our PhysChem and Nomenclature algorithms will enable chemists direct access to these essential properties. ACD/Labs is pleased to provide our customers with higher levels of integration through the Kalabie interface."
Modified Form of Botox Could Replace Opioids as Treatment for Chronic PainNews
A modified form of botulinum toxin gives long-lasting pain relief in mice without adverse effects and, in time, could replace opioid drugs as a safe and effective way of treating chronic pain, according to new research.READ MORE
Key Ingredient in Diabetes Drug Modified to Improve Side EffectsNews
Improved medications for Type 2 diabetes are one step closer thanks to a new discovery reported this week. By modifying the key ingredient in current diabetes drugs, the researchers produced a compound that was effective for hyperglycemia in animal trials, yet without the most problematic side effects of current drugs.READ MORE
Tackling Cancer at Ground Zero: Designer Molecule Inhibits Protein TargetNews
A new molecule designed by University of Adelaide researchers shows great promise for future treatment of many cancers. The new molecule successfully targets a protein that plays a major role in the growth of most cancers.READ MORE